Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT ID: NCT06479135
Last Updated: 2025-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
600 participants
INTERVENTIONAL
2024-06-03
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Subjects will start by receiving ruxolitinib alone in the run-in period. Those who demostrate a suboptimal response from ruxolitinib alone will then be randomized 2:1 to receive navtemadlin or navtemadlin placebo as add-on treatment to their ongoing ruxolitinib. Randomized means that subjects will be assigned to a group by chance, like a flip of a coin. The study is blinded, meaning the subjects, doctors, central endpoint assessors and sponsor will not know which add on treatment (navtemadlin or navtemadlin placebo) the subject is receiving.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
NCT03222609
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
NCT04468984
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
NCT06773195
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
NCT04472598
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
NCT04454658
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Navtemadlin administered orally once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles. Ruxolitinib administered orally twice a day.
Navtemadlin
Navtemadlin is an investigational MDM2 inhibitor
Ruxolitinib
Ruxolitinib is a janus kinase 1/2 inhibitor
Arm 2
Navtemadlin placebo administered orally once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles. Ruxolitinib administered orally twice a day.
Navtemadlin placebo
Navtemadlin placebo
Ruxolitinib
Ruxolitinib is a janus kinase 1/2 inhibitor
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Navtemadlin
Navtemadlin is an investigational MDM2 inhibitor
Navtemadlin placebo
Navtemadlin placebo
Ruxolitinib
Ruxolitinib is a janus kinase 1/2 inhibitor
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* High, Intermediate-1, Intermediate-2 risk category International Prognosis System Score (IPSS)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
* JAK-inhibitor treatment naive
* PMF, post-PV MF, or post-ET MF that is TP53WT as assessed by central testing
* ECOG performance status of 0 to 2
* Treatment with a stable dose of ruxolitinib
* Suboptimal response to run-in ruxolitinib treatment
Exclusion Criteria
* Splenic irradiation within 3 months prior to the first dose
* Prior BCL-XL, BET, MDM2, PI3K, PIM, or XPO1 inhibitors therapy or p53-directed therapy
* Eligible for Bone Marrow Transplant
* Peripheral blood or bone marrow blast count ≥ 10 percent
* Elevated white blood cell count that doubles (or more) during ruxolitinib treatment and exceeds 50 × 10\^9/L
* Peripheral blood or bone marrow blast count ≥ 10 percent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kartos Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UAB Hospital
Birmingham, Alabama, United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
Mayo Clinic - Phoenix
Phoenix, Arizona, United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
UCLA Hematology/Oncology Clinic - Los Angeles
Los Angeles, California, United States
Scripps Health, Prebys Cancer Center
San Diego, California, United States
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California, United States
Rocky Mountain Cancer Centers - Aurora
Aurora, Colorado, United States
Medical Oncology Hematology Consultants, PA
Newark, Delaware, United States
MedStar Georgetown University Hospital, Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States
University of Miami
Miami, Florida, United States
AdventHealth Cancer Institute
Orlando, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Mission Cancer + Blood
Des Moines, Iowa, United States
University of Kansas Cancer Center - Westwood
Westwood, Kansas, United States
Norton Cancer Institute
Louisville, Kentucky, United States
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
The Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
University of Michigan Hospital
Ann Arbor, Michigan, United States
Henry Ford Cancer Institute - Brigitte Harris Cancer Pavilion
Detroit, Michigan, United States
Nebraska Hematology - Oncology, P.C.
Lincoln, Nebraska, United States
Mohtaseb Cancer Center and Blood Disorders
Henderson, Nevada, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Brookdale University Hospital and Medical Center
Brooklyn, New York, United States
Cayuga Cancer Center
Ithaca, New York, United States
Northwell Health, R.J. Zuckerberg Cancer Center
Lake Success, New York, United States
ICAHN School of Medicine at Mount Sinai
New York, New York, United States
Montefiore Einstein Comprehensive Cancer Center
The Bronx, New York, United States
Medical University of South Carolina (MUSC)
Charleston, North Carolina, United States
Atrium Health Levine Cancer Institute
Charlotte, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
Regional Medical Oncology Center
Wilson, North Carolina, United States
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, United States
Gabrail Cancer Center
Canton, Ohio, United States
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio, United States
Cleveland Clinic
Cleveland, Ohio, United States
Independence Family Health Center - Cleveland Clinic
Independence, Ohio, United States
Hillcrest Hospital - Cleveland Clinic
Mayfield Heights, Ohio, United States
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, United States
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
West Penn Hospital
Pittsburgh, Pennsylvania, United States
Tennessee Oncology
Chattanooga, Tennessee, United States
Tennessee Oncology
Nashville, Tennessee, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
UT - SouthWestern
Dallas, Texas, United States
U.T. MD Anderson Cancer Center
Houston, Texas, United States
The University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, United States
Virginia Cancer Institute
Richmond, Virginia, United States
VCU Medical Center
Richmond, Virginia, United States
Virginia Oncology Associates - Virginia Beach
Virginia Beach, Virginia, United States
Fred Hutchinson Cancer Centre
Seattle, Washington, United States
Northwest Medical Specialties, PLLC - Tacoma
Tacoma, Washington, United States
Sheboygan Cancer & Blood Specialists
Sheboygan, Wisconsin, United States
Royal Hobart Hospital (RHH)
Hobart, Tasmania, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
Royal Adelaide Hospital
Adelaide, , Australia
Monash Medical Center Clayton
Clayton, , Australia
Townsville University Hospital
Douglas, , Australia
Gosford Hospital
Gosford, , Australia
St George Hospital
Kogarah, , Australia
The Royal Melbourne Hospital - Peter MacCallum Cancer Center
Melbourne, , Australia
The Alfred Hospital
Melbourne, , Australia
Royal Perth Hospital
Perth, , Australia
Calvary Mater Newcastle Hospital
Waratah, , Australia
University Hospital Graz, Department of Internal Medicine
Graz, , Austria
Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology)
Innsbruck, , Austria
Regional Hospital Hochsteiermark - Leoben, Department of Internal Medicine, Department of Hematology and Oncology
Leoben, , Austria
Ordensklinikum Linz GmbH Elisabethinen Hospital, Department of Internal Medicine I - Hemato-Oncology
Linz, , Austria
Kepler University Hospital GmbH, Med Campus 3, University Clinic for Hematology and Internal Oncology
Linz, , Austria
Medical University Vienna
Vienna, , Austria
Hospital Ottakring, Department of Internal Medicine I
Vienna, , Austria
Antwerp Hospital Network (ZNA) Cadix
Antwerp, , Belgium
University Hospitals Leuven, Campus Gasthuisberg
Leuven, , Belgium
University Hospital Center Sart-Tilman
Liège, , Belgium
General Hospital Delta
Roeselare, , Belgium
UCL Mont-Godinne University Hospitals
Yvoir, , Belgium
Clinical Hospital Centre Rijeka
Rijeka, , Croatia
University Hospital of Split
Split, , Croatia
General Hospital of Sibenik-Knin County
Šibenik, , Croatia
Clinical Hospital Dubrava
Zagreb, , Croatia
Clinical Hospital Merkur
Zagreb, , Croatia
Solmed Clinic
Zagreb, , Croatia
University Hospital Centre Zagreb
Zagreb, , Croatia
University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology
Brno, , Czechia
University Hospital Hradec Kralove
Hradec Králové, , Czechia
University Hospital Ostrava
Ostrava, , Czechia
University Hospital Kralovske Vinohrady
Prague, , Czechia
Institute of Hematology and Blood Transfusion
Prague, , Czechia
Saint-Louis Hospital, Department of Adult Hematology
Paris, Paris, France
Amiens Picardie University Hospital - South
Amiens, , France
Angers University Hospital Center
Angers, , France
Lille Regional University Hospital Center
Lille, , France
South Lyon Hospital Center
Lyon, , France
Leon Berard Center
Lyon, , France
Nantes University Hospital Center - Hotel Dieu Hospital
Nantes, , France
Archet 1 and 2 hospital
Nice, , France
Nimes University Hospital Center, Department of Clinical Hematology and Medical Oncology
Nîmes, , France
Bordeaux University Hospital
Pessac, , France
University Hospital Center of Poitiers
Poitiers, , France
Strasbourg Europe Institut of Cancerology
Strasbourg, , France
University Hospital of Toulouse, IUCT-Oncopole
Toulouse, , France
Tours Regional University Hospital Center
Tours, , France
JSC Vian
Kutaisi, , Georgia
JSC German Hospital
Tbilisi, , Georgia
LEPL The First University Clinic of Tbilisi State Medical University
Tbilisi, , Georgia
Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic LLC
Tbilisi, , Georgia
JSC K. Eristavi National Center of Experimental and Clinical Surgery
Tbilisi, , Georgia
Caucasus Medical Centre LLC
Tbilisi, , Georgia
Marien Hospital Duesseldorf GmbH
Düsseldorf, , Germany
University Hospital Freiburg
Freiburg im Breisgau, , Germany
University Hospital Halle (Saale)
Halle, , Germany
University Hospital Hamburg-Eppendorf
Hamburg, , Germany
Hannover Medical School
Hanover, , Germany
University Hospital Heidelberg
Heidelberg, , Germany
University Hospital Jena
Jena, , Germany
University Hospital Schleswig-Holstein
Kiel, , Germany
MVZ Mitte Am Johannisplatz
Leipzig, , Germany
Hospital Rechts der Isar
Munich, , Germany
Staufer Schwaebisch Gmuend Hospital
Mutlangen, , Germany
Hospital Nuernberg, Campus North
Nuremberg, , Germany
Robert-Bosch-Hospital
Stuttgart, , Germany
University Hospital Ulm
Ulm, , Germany
General Hospital of Athens Laikon
Athens, , Greece
University General Hospital "Attikon"
Athens, , Greece
University General Hospital of Ioannina
Ioannina, , Greece
University General Hospital of Patras
Pátrai, , Greece
General Hospital of Thessaloniki "G. Papanikolaou"
Thessaloniki, , Greece
Semmelweis University
Budapest, , Hungary
Szabolcs-Szatmar-Bereg County Teaching Hospital
Nyíregyháza, , Hungary
Tolna County Hospital
Szekszárd, , Hungary
Fejer County St. Gyorgy University Teaching Hospital
Székesfehérvár, , Hungary
National Hospital SS. Antonio e Biagio e Cesare Arrigo
Alessandria, , Italy
Marche University Hospital
Ancona, , Italy
Polyclinic S. Orsola-Malpighi
Bologna, , Italy
ASST Spedali Civili Brescia
Brescia, , Italy
University Hospital "G.Rodolico - San Marco"
Catania, , Italy
Careggi University Hospital
Florence, , Italy
Institute of Romagna for Cancer Research " Dino Amadori" - IRCCS IRST
Forlì, , Italy
Maggiore Polyclinic Hospital, Foundation IRCCS Ca' Granda
Milan, , Italy
European Institute of Oncology (IEO), IRCCS
Milan, , Italy
University Hospital "Maggiore della Carita" of Novara
Novara, , Italy
University Hospital San Luigi Gonzaga
Orbassano, , Italy
University Polyclinic Hospital "Paolo Giaccone" Palermo
Palermo, , Italy
Polyclinic San Matteo, IRCCS
Pavia, , Italy
Local Health Company of Pesaro and Urbino
Pesaro, , Italy
Hospital Arcispedale S. Maria Nuova of Reggio Emilia
Reggio Emilia, , Italy
Hospital S. Eugenio- Rome 2 ASL
Rome, , Italy
City of Health and Science of Turin
Turin, , Italy
ASST Sette Laghi Hospital
Varese, , Italy
"InterHem" General Partnership
Bialystok, , Poland
University Teaching Centre, Hematology and Transplantology Clinic
Gdansk, , Poland
Independent Public Healthcare Facility University Hospital in Krakow
Krakow, , Poland
Nicolaus Copernicus Provincial Multispecialty Oncology and Traumatology Center
Lodz, , Poland
Jedrzej Sniadecki Specialist Hospital in Nowy Sacz
Nowy Sącz, , Poland
Oncology Center of Warmia and Mazury in Olsztyn
Olsztyn, , Poland
AIDPORT
Poznan, , Poland
Dom Lekarski Medical Center Outlet Park
Szczecin, , Poland
Janusz Korczak Provincial Specialist Hospital
Słupsk, , Poland
Clinical Best Solutions LLC, Limited Partnership
Warsaw, , Poland
Dr Alfred Sokolowski Specialty Hospital
Wałbrzych, , Poland
Jan Mikulicz-Radecki Teaching Hospital in Wroclaw
Wroclaw, , Poland
Hospital Center of Baixo Vouga -Aveiro Unit - Hospital Infante D. Pedro
Aveiro, , Portugal
Braga Hospital
Braga, , Portugal
Central Hospital of Western Lisbon
Lisbon, , Portugal
Centro Hospitalar Lisboa Norte (CHLN) EPE - Hospital de Santa Maria
Lisbon, , Portugal
Vila Nova de Gaia Central Hospital
Vila Nova de Gaia, , Portugal
Onco Card Srl
Brasov, , Romania
Colentina Clinical Hospital, Department of Hematology
Bucharest, , Romania
"Prof. Dr. Ion Chiricuta" Institute of Oncology, Hematology Department
Cluj-Napoca, , Romania
Bihor County Emergency Clinical Hospital, Department of Hematology
Oradea, , Romania
Targu Mures County Emergency Clinical Hospital, Internal Medicine Department I, Hematology Unit
Târgu Mureş, , Romania
University Clinical Center of Serbia
Belgrade, , Serbia
Clinical Hospital Center Bezanijska Kosa
Belgrade, , Serbia
University Clinical Center Kragujevac
Kragujevac, , Serbia
Clinical Center of Vojvodina
Novi Sad, , Serbia
Inje University Busan Paik Hospital
Busan, , South Korea
Pusan National University Hospital
Busan, , South Korea
Kyungpook National University Hospital
Daegu, , South Korea
Keimyung University - Dongsan Medical Center
Daegu, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Soon Chun Hyang University Hospital Seoul
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, , South Korea
University Hospital Germans Trias i Pujol
Badalona, , Spain
University Hospital Vall d'Hebron
Barcelona, , Spain
Catalan Institute of Oncology, Hospital Duran i Reynals
Barcelona, , Spain
Caceres Hospital Complex - San Pedro de Alcantara General Hospital
Cáceres, , Spain
Gran Canaria Dr Negrin University Hospital
Las Palmas de Gran Canaria, , Spain
University Hospital 12 de Octubre
Madrid, , Spain
University Hospital Ramon y Cajal
Madrid, , Spain
University Hospital Virgen de la Victoria
Málaga, , Spain
University Clinical Hospital of Salamanca
Salamanca, , Spain
University Clinical Hospital of Valencia
Valencia, , Spain
University and Polytechnic Hospital La Fe
Valencia, , Spain
Quironsalud Zaragoza Hospital
Zaragoza, , Spain
Birmingham Heartlands Hospital
Birmingham, , United Kingdom
Lincoln County Hospital
Boston, , United Kingdom
Pilgrim Hospital
Boston, , United Kingdom
Addenbrooke's Hospital
Cambridge, , United Kingdom
University Hospital of Wales
Cardiff, , United Kingdom
Western General Hospital, Lothian Health Board
Edinburgh, , United Kingdom
Gloucestershire Royal Hospital
Gloucester, , United Kingdom
Harrogate District Hospital
Harrogate, , United Kingdom
Leicester Royal Infirmary
Leicester, , United Kingdom
The Clatterbridge Cancer Center NHS Foundation Trust
Liverpool, , United Kingdom
University College Hospital
London, , United Kingdom
Guy's Hospital
London, , United Kingdom
Genesis Care, Oxford
Oxford, , United Kingdom
Genesis Care, Windsor
Windsor, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KRT-232-115
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.